Aims: To evaluate whether treatment with LY2409021, a novel, selective glucagon receptor antagonist, is associated with changes in hepatic fat and other safety variables related to the benefit-risk profile for chronic use in patients with type 2 diabetes (T2D).
| INTRODUCTION
Glucagon, a 29-amino-acid peptide released from the α cells of the islets of Langerhans, plays a key role in glucose homeostasis. 1, 2 Glucagon action is transduced by the class B G-protein-coupled glucagon receptor (GCGR), located on liver, kidney, intestinal smooth muscle, brain, adipose tissue, heart and pancreas cells. 1, 2 After carbohydrate ingestion in healthy individuals, glucagon secretion is suppressed, reducing glucagon-induced stimulation of hepatic glucose production. 3 The pathophysiology of type 2 diabetes mellitus (T2D)
is characterized not only by insulin resistance and β-cell dysfunction, but also by hyperglucagonaemia in the fasting state and abnormal glucagon suppression after a meal. 4 Administration of recently identified small-molecule GCGR antagonists in patients with T2D results in a substantial reduction of fasting and postprandial glucose concentrations and has made antagonism of the glucagon receptor an attractive target for the treatment of T2D. 3 In addition to its effects on carbohydrate metabolism, glucagon is known to exert effects on lipid metabolism, including promoting fatty acid oxidation in hepatocytes. 5 LY2409021 is a novel agent that competitively blocks the GCGR.
It has a long half-life (approximately 60 hours) and is administered orally once daily. While several studies with LY2409021 have demonstrated a significant glycaemic-lowering effect in patients with T2D, results have also shown dose-dependent and reversible increases in hepatic aminotransferase levels. 6 The present study was designed to further assess the risk-benefit profile of LY2409021, and to investigate the mechanism underlying the increases in hepatic aminotransferases and assess their correlation with changes in hepatic fat.
| MATERIALS AND METHODS

| Study design and patients
This phase IIb, randomized, double-blind, placebo-and active comparator-controlled study (ClinicalTrials.gov NCT02111096) was conducted at 35 study centres in 3 countries, in accordance with regulatory standards of good clinical practice, the Declaration of Helsinki and all applicable local regulations. The protocol was approved by each site's ethical review board. All patients provided written informed consent before initiation of study procedures.
Patients were men and women, aged ≥18 and <80 years, with a diagnosis of T2D, 7 who were on an optimally effective and stable dose of metformin and a sulphonylurea, had glycated haemoglobin >90 mm Hg; current use of systemic glucocorticoid therapy, amiodarone, methotrexate, isoniazid or tamoxifen; and an average weekly alcohol intake exceeding 2 units per day for men and 1 unit per day for women. Full inclusion and exclusion criteria can be found in the Supporting Information (Appendix S1).
The present study was originally designed with a primary endpoint after 6 months of treatment and a total treatment period of 12 months; however, the decision to terminate early was made based on results from a dedicated ambulatory blood pressure monitoring study, which showed an increase in blood pressure with LY2409021 treatment. 8 The sponsor determined that the overall risk-benefit profile of LY2409021 was unlikely to support its use as a chronic treatment for T2D. At that time, investigators in the present study were instructed to take their patients off study medication and complete the 4-month post-treatment safety follow-up visit.
| Randomization and masking
Patients who met all criteria for enrolment were randomized to double-blinded LY2409021, placebo, or sitagliptin in a 3:3:2 ratio by a computer-generated random sequence procedure. Stratification was based on country and baseline HbA1c level (≤8.0%, >8.0%). Participants, caregivers and study personnel were masked to treatment assignment. Members of an independent Assessment Committee had access to unmasked data reports, but had no contact with study sites or participants.
| Procedures
The study consisted of a 1-week screening period, a 2-week lead-in period, and a 12-month placebo-and active-control period, followed by a 4-month post-treatment safety follow-up period and an addi- Fasting samples for plasma glucagon were taken in duplicate and analysed using a novel high-sensitivity electrochemiluminescence sandwich immunoassay. 9 Other clinical chemistry endpoints were measured using commercially validated methods; LDL cholesterol was calculated using the Friedewald formula. Anthropometry was completed according to standard procedures; blood pressure and pulse were recorded in triplicate throughout the study. Selfmonitoring of blood glucose and glucose levels at study visits were used to determine episodes of hypoglycaemia.
| Outcome measurements
The primary outcome of the present study was to compare the effects of LY2409021 vs placebo on the liver fat change from baseline to month 6. Key secondary outcomes of the study were to compare the effects of LY2409021 with those of sitagliptin on the HFF change from baseline to month 6 and month 12, as well as comparisons of effects of LY2409021 vs placebo and vs sitagliptin on the following variables: hepatic aminotransferases; HbA1c; fasting plasma glucose; fasting glucagon; fasting lipids; vital signs; body weight; and hypoglycaemia incidence.
| Statistical analysis
Sample size determination was based on the comparison of the LY2409021 treatment arm with the placebo arm with regard to the change in HFF to month 6. Approximately 60 patients per arm were needed to achieve >90% power to detect a treatment difference of 6%, assuming a standard deviation (s.d.) of 8%, a 20% dropout rate, and 25% of patients without a usable HFF measure at the 6-month visit. 10 Analysis of the primary endpoint was based on a modified intention-to-treat population, defined as all randomized patients who received at least 1 dose of study drug and had a usable baseline HFF and at least 1 usable post-baseline measure. Efficacy and other safety analyses were conducted on the intention-to-treat population, defined as all randomized patients who received at least 1 dose of randomized study drug.
The primary and key secondary outcome analyses were conducted for the 6-month treatment period excluding data after use of rescue therapy. Other safety analyses included all data regardless of rescue therapy or use of investigational product unless otherwise specified. As a result of the early termination of the trial, limited data were available for the 12-month treatment period; therefore, only summary data for HFF and hepatic aminotransferases are presented for month 12.
Continuous efficacy and safety variables measured repeatedly were 3 | RESULTS
| Patient disposition and baseline characteristics
A total of 174 patients were randomly assigned to treatment: LY2409021, n = 65; placebo, n = 68; and sitagliptin, n = 41
( Figure S1 ). The treatment groups were mostly well balanced with regard to demographics and baseline characteristics (Table 1) . A total of 132 patients completed 6 months (primary endpoint of the study).
The median exposure was 242 days for LY2409021, 225 days for placebo, and 251 days for sitagliptin.
| Outcomes 3.2.1 | Hepatic safety
The majority of patients had steatosis at baseline (HFF >5.5%). 11 The mean HFF for each group was 11% to 15%, but individual patients had baseline HFF as low as 1.3% and as high as 42%. At month 6, treatment with LY2409021 resulted in a statistically significant increase in HFF compared with placebo and sitagliptin ( Figure 1A ). 
| Glycaemic-related efficacy measurements
At month 6, there was a statistically significant reduction in HbA1c
for the LY2409021 treatment group compared with placebo but not sitagliptin ( Figure 3 ). Similar results were observed for fasting plasma glucose (Supporting Information, Appendix S1). In addition, a statistically significantly higher percentage of patients attained HbA1c targets of ≤6.5% and <7% in the LY2409021 group compared with placebo and sitagliptin (Appendix S1 
| Haemodynamic effects
At month 6, a statistically significant increase in SBP was observed in the LY2409021 treatment group compared with sitagliptin and placebo ( Figure 4A ). LY2409021 also led to numerically greater, but not statistically significant, increases in DBP compared with sitagliptin and placebo ( Figure 4B ). At 4 months post-treatment, mean SBP and were no statistically significant treatment differences in change from baseline to month 6 for pulse rate.
| Anthropometric effects
A statistically significant increase in weight was observed at month 6 for LY2409021 compared with sitagliptin (1.16 vs −0.23 kg; P = .007) and placebo (1.16 vs −0.08 kg; P = .006; Figure S3 ). At 4 months post-treatment, mean weight had returned to or was near baseline levels in all groups.
| Correlations
Changes in HFF were positively correlated with changes in ALT (P < .001) and AST (P < .001) for LY2409021; a positive correlation between HFF and ALT was also observed for placebo (P = .038). *** *** *** FIGURE 3 Change in HbA1c from baseline to month 6. LY, LY2409021; SITA, sitagliptin For LY2409021, changes in HFF were not significantly correlated with changes in fasting plasma glucagon or total cholesterol. In addition, changes in fasting plasma glucagon were not correlated with changes in vital signs for LY2409021.
| Adverse events
A serious AE of hypertensive crisis, not related to study treatment, was reported in an LY2409021-treated patient. There were no liverrelated serious AEs. Additional AE data are included in Appendix S1.
Total hypoglycaemia incidence up to month 6 was significantly higher with LY2409021 than placebo (48.4% vs 19.1%; P < .001) but similar to sitagliptin (48.4% vs 47.5%; P = .993). There were no events of severe hypoglycaemia in any group.
| DISCUSSION
Inhibition of glucagon action represents a clinically validated new approach to reduction of hyperglycaemia, and a compelling therapeutic option for T2D. 12, 13 There are currently several molecules in dif- There are drawbacks with antagonism of GCGR. The most common side effect reported with glucagon receptor antagonist therapy is hepatic aminotransferase elevation. [15] [16] [17] [20] [21] [22] Another potential concern is malignant transformation of α cells as they undergo marked hyperplasia when the action of their secretory product is blocked. 19 In fact, the clinical development of 2 glucagon receptor antagonists, BAY 27-955 and MK-0893, has been abandoned; 23 for MK-0893, side effects including hypertension, elevated aminotransferases, weight gain and unfavourable changes in lipid profile have been reported. 20, 21 The findings in the present study included significant hepatic fat accumulation and an increase in blood pressure on a background of persistent hepatic aminotransferase elevations in patients exposed to LY2409021. Increases in total cholesterol and body weight were also observed. These effects have not been previously demonstrated with LY2409021 treatment but some have been reported, together with hepatic aminotransferase elevations, for MK-0893 and PF-06291874, 16, 20, 21 suggesting that such changes may be related to the mechanism itself.
The mechanism behind HFF accumulation and increases in hepatic aminotransferase levels during glucagon receptor antagonist treatment is unclear. Glucagon exerts multiple hypolipidaemic actions directly on hepatocytes, in part through a PPARα-dependent pathway. 13 Studies have shown that high fat feeding of GCGR −/− mice was associated with accelerated development of steatosis in some but not all studies. 13 The findings in animals involving multiple GCGR −/− species, together with novel results from the present study in humans, imply that a threshold level of GCGR signalling is required for hepatocytes to regulate synthesis, secretion and oxidation of lipids, and marked attenuation of GCGR signalling would be predicted Change from baseline to month 6 in A, SBP and B, DBP. Note: blood pressure (BP) calculated as mean of 3 readings. LY, LY2409021; SITA, sitagliptin to be associated with an increased risk of dyslipidaemia and fatty liver. Although reversible after treatment discontinuation, significant HFF increases with elevations in hepatic aminotransferases are unwanted side effects for long-term treatment of patients with T2D, a population already at risk of non-alcoholic fatty liver disease. 24 Elevations in blood pressure observed for LY2409021 support findings from a separate ambulatory blood pressure monitoring study with LY2409021. 8 Moreover, increases in blood pressure have also been observed with MK-0893 and PF-06291874. 16, 21 This suggests that, in addition to elevations in hepatic aminotransferases, elevations in blood pressure may be an untoward side effect in common with this class of molecules.
Consistent with weight gain reported with MK-0893, 20 LY2409021 is the second glucagon receptor antagonist to demonstrate an increase in body weight, although this was not always observed in other studies.
A limitation of the present study was the early termination of the trial, which prevented the collection and analysis of the complete 12-month data. Also, the lack of liver biopsies precludes meaningful conclusions regarding the development of steatohepatitis 25, 26 or other histological evidence of liver injury. Nonetheless, we believe that this well-powered study, which longitudinally evaluated multiple safety and efficacy endpoints vs placebo and active comparator, provides a robust assessment of the benefit-risk profile of LY2409021.
Although α-cell hyperplasia has been identified as a potential long-term treatment concern for glucagon receptor antagonists, 19 our results show other safety side effects that can manifest as early as 1 month after treatment initiation. Data from this trial recapitulate findings from other trials with different glucagon receptor antagonists and show for the first time that this mechanism is associated with significant hepatic fat accumulation, along with elevations in hepatic aminotransferases, blood pressure, lipid variables and body weight.
Taken together, although this mechanism may carry appeal for its glucose-lowering efficacy, some of the attendant adverse effects raise questions regarding the suitability of glucagon receptor antagonism as a chronic treatment for T2D.
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